(intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer
نویسندگان
چکیده
A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human a m integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer A. Heidenreich1,, S. K. Rawal2, K. Szkarlat3, N. Bogdanova4, L. Dirix5, A. Stenzl6, M. Welslau7, G. Wang8, F. Dawkins9, C. J. de Boer10 & D. Schrijvers11 Department of Urology, University Hospital of Cologne, Cologne; Department of Uro-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India; Urological Ward, Koscierzyna Hospital, Koscierzyna, Poland; P. A. Hertzen Oncology Research Institute, Moscow, Russia; Department of Cancer Research, GZA Hospitals St. Augustine Campus, Wilrijk, Belgium; Department of Urology, Eberhard-Karls University, Tübingen; Hematology/Oncology, Studienzentrum, Aschaffenburg, Germany; Biostatistics, Janssen Research & Development, Spring House; Hematology & Oncology General, Janssen Research & Development, Raritan, USA; Oncology, Janssen Biologics Europe, Leiden, The Netherlands; Medical Oncology, Hospital Network Antwerp (ZNA)-Middelheim, Antwerp, Belgium
منابع مشابه
[Management of patients with castration-resistant metastatic prostate cancer].
Prostate cancer belongs to the most common malignant tumors in males. Almost in all patients in advanced stage, disease progression occurs despite of castration therapy. Initial treatment of metastatic disease is androgen deprivation therapy. In the case of castration-resistant disease development in asymptomatic patients, it is a combination of abiraterone acetate plus prednisone and in sympto...
متن کاملCabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
Until recently, patients with castration-resistant prostate cancer (CRPC) had limited therapeutic options once they became refractory to docetaxel chemotherapy, and no treatments improved survival. This changed in June 2010 when the Food and Drug Administration (FDA) approved cabazitaxel as a new option for patients with CRPC whose disease progresses during or after docetaxel treatment. For mos...
متن کاملEvolving role of chemotherapy in castration-resistant prostate cancer
The role of chemotherapy in castration-resistant prostate cancer has evolved greatly over the past several decades. However, at this time, docetaxel remains the only first-line chemotherapy option that improves survival. More recently, the novel taxane cabazitaxel (plus prednisone) was found to prolong overall survival in metastatic castration-resistant patients who had progressed during or aft...
متن کاملAbiraterone acetate for metastatic castration-resistant prostate cancer post-docetaxel
Abiraterone acetate (AA) 1000-mg daily, a selective irreversible androgen biosynthesis inhibitor of cytochrome P450 c17 (CYP17) enzyme, is used in combination with prednisone 10-mg daily to treat docetaxel-treated patients with metastatic castration-resistant prostate cancer (mCRPC). Several studies have demonstrated the safety and efficacy of this compound in men with mCRPC. Interim results fr...
متن کاملKnockdown of HSF1 sensitizes resistant prostate cancer cell line to chemotherapy
The treatment of prostate cancer patients usually starts with androgen ablation and followed by chemotherapy; however, in some cases the tumor develops resistant phenotype. Combination therapy is currently regarded as a cornerstone in cancer therapy to overcome the drug resistance. Herein, we investigated the combinatory effect of Docetaxel and Trastuzumab with a novel nanomedicine, BCc1. Also,...
متن کامل